Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This system overview describes the UTokyo Repository's role in storing and providing online access to digital resources from the University of Tokyo, reporting no new empirical findings or research results.

In this first-in-human study, BLZ-100, an intraoperative fluorescent imaging agent, was administered to 21 patients before skin cancer surgery and was found to be well tolerated without serious adverse effects, suggesting its potential to help distinguish cancerous from non-cancerous tissue based on fluorescence.

This abstract does not contain research results or findings.

This study reported that ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel, showed promising antitumor activity and was safe and well-tolerated in preclinical models and a phase I trial, without acute hypersensitivity reactions at doses up to 390 mg/m².

The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.

This study found that shorter GGN repeat lengths (≤23) in the androgen receptor gene are associated with androgenetic alopecia among Chinese males, whereas two specific SNPs studied were not present in this population.

This study developed a precise and simple HPLC method for estimating tamsulosin and finasteride simultaneously in pharmaceutical forms, demonstrating good precision and potential usefulness for combined dosage analysis.

This article reviews advancements in carbon dots for tissue engineering and regenerative medicine, highlighting challenges and future directions without presenting new clinical findings.

This case study reports that a patient receiving Bojungikki-tang alongside chemotherapy showed improvement in hair loss despite ongoing treatment, suggesting a potential benefit for chemotherapy-induced alopecia.

In this study, researchers identified a specific T cell receptor associated with carbamazepine-induced severe cutaneous adverse reactions, demonstrating its potential for therapeutic development in patients with the HLA-B*15:02 genotype.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

This study successfully developed and validated a reverse-phase HPLC method for accurately determining finasteride and tamsulosin simultaneously in bulk and pharmaceutical formulations.

This report analyzed an FDA adverse event database and aimed to evaluate and describe post-finasteride syndrome potentially related to dutasteride, but it does not report new clinical findings.

This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.

Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.

This source describes a collection of geometric medicine formulations aimed at comprehensive hair restoration and permanent hair removal, with claimed simulation results indicating complete baldness reversal and effective hair removal, but results are sourced from theoretical and simulation-based findings without reported clinical trials.

This case report documents new hair growth in a 57-year-old man with androgenic alopecia after receiving gefitinib treatment for non-small-cell lung cancer.

This study found that the novel IPC analog SIG-1451 may inhibit inflammatory cytokine release in cell-based assays relevant to allergic dermatitis.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

In this study, PMC was identified as a promising plant for nourishing hair, with effective hair growth promotion and 5α-reductase inhibition observed in both laboratory and animal studies for androgenetic alopecia treatment.

The study found that cyproterone acetate could be released over 15 days using coconut oil mixed with certain wax inhibitors, though further safety studies are needed.

The document's conclusion cannot be determined as the content is not available.